Zobrazeno 1 - 10
of 437
pro vyhledávání: '"sglt2 inhibition"'
Publikováno v:
Cardiologia Hungarica, Vol 54, Iss 3, Pp 177-182 (2024)
The year 2023 proved to be a productive period with many remarkable scientific papers published from Hungary in the field of heart failure (HF). Our aim with this brief review is to highlight the results of the most prominent landmark randomized clin
Externí odkaz:
https://doaj.org/article/79070191c5d748bca41a736a8e3627d4
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundWhile Sodium-glucose cotransporter 2 (SGLT2) inhibitors are effective in managing diabetes and reducing cardiovascular risk, concerns about their association with lower limb complications, including, osteomyelitis, ulcers, and peripheral ar
Externí odkaz:
https://doaj.org/article/da444abe5e18442f9086fefccd01e347
Autor:
Gailing Liu
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
AimSodium-glucose cotransporter protein 2 (SGLT2) inhibitors have been shown to have renoprotective effects in clinical studies. For further validation in terms of genetic variation, drug-targeted Mendelian randomization (MR) was used to investigate
Externí odkaz:
https://doaj.org/article/1735342131fe4c2a9c60a13e173b8b7c
Publikováno v:
Kidney Medicine, Vol 6, Iss 7, Pp 100839- (2024)
5-Amino salicylic acid (5-ASA) is a known culprit for the development of tubulointerstitial nephritis. Together with impaired kidney function, tubulointerstitial nephritis can lead to specific tubular malfunctions including distal renal tubular acido
Externí odkaz:
https://doaj.org/article/605dd1eb868b4c35bc07ad04afb8364b
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
ObjectiveTo investigate the causal role of venous thrombolism mediating sodium-glucose cotransporter 2 (SGLT2) inhibition in death due to cardiac causes using Mendelian randomization (MR).MethodsA two-sample two-step MR was used to determine (1) the
Externí odkaz:
https://doaj.org/article/ad586a1b342c48bcbe2b9fc25f1830b8
Autor:
William Barbour, Erika Wolff, Pankaj Puar, Makoto Hibino, Ehab Bakbak, Aishwarya Krishnaraj, Raj Verma, Meena Verma, Adrian Quan, Andrew T. Yan, Kim A. Connelly, Hwee Teoh, C. David Mazer, Subodh Verma
Publikováno v:
BMC Cardiovascular Disorders, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background This exploratory sub-analysis of the EMPA-HEART CardioLink-6 trial examined whether the previously reported benefit of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin on left ventricular (LV) mass (LVM) regressi
Externí odkaz:
https://doaj.org/article/098a1e7724b54b69ab9de1d8e4f93108
Autor:
Pankaj Puar, Makoto Hibino, C. David Mazer, Andrew T. Yan, Arjun K. Pandey, Adrian Quan, Hwee Teoh, David A. Hess, Raj Verma, Kim A. Connelly, Subodh Verma
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-8 (2023)
Abstract Background The cardiovascular (CV) benefits of sodium-glucose transport protein 2 inhibitors have been attributed, in part, to cardiac reverse remodelling. The EMPA-HEART CardioLink-6 study reported that sodium-glucose cotransporter-2 inhibi
Externí odkaz:
https://doaj.org/article/ab616f36e927471c96ec9a99369e168c
Autor:
Kentaro Oka, Takahiro Masuda, Ken Ohara, Marina Miura, Masato Morinari, Kyohei Misawa, Yasuharu Miyazawa, Tetsu Akimoto, Kazuyuki Shimada, Daisuke Nagata
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Sodium glucose cotransporter 2 (SGLT2) inhibitors have both glucose-lowering and diuretic effects. We recently reported that the SGLT2 inhibitor dapagliflozin exerts short-term fluid homeostatic action in patients with chronic kidney disease (CKD). H
Externí odkaz:
https://doaj.org/article/b2b3a875202b4264856082e8e140a1a2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Frederick Sinha, Anna Federlein, Annika Biesold, Magdalena Schwarzfischer, Katharina Krieger, Frank Schweda, Philipp Tauber
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
The inhibition of renal SGLT2 glucose reabsorption has proven its therapeutic efficacy in chronic kidney disease. SGLT2 inhibitors (SGLTi) have been intensively studied in rodent models to identify the mechanisms of SGLT2i-mediated nephroprotection.
Externí odkaz:
https://doaj.org/article/715ee4e21af541b8bc6e91d1b325228e